Latest Information Update: 07 Apr 1999
$50 / €47 *
At a glance
- Originator AstraZeneca
- Class Antiglaucomas
- Mechanism of Action Beta-adrenergic receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Glaucoma
Most Recent Events
- 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed.
- 30 May 1995 New profile
- 30 May 1995 Discontinued-Preclinical for Glaucoma in Sweden (Unknown route)